Patent ID: 11944689
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 11:
12. The Ligand Drug Conjugate compound of claim 1 wherein -D+ is a quaternized tubulysin Drug Unit having the structure of:, in pharmaceutically acceptable salt form, wherein
subscript m is 0 or 1;
R2A is hydrogen or optionally substituted C1-C12 alkyl, or R2A along with the oxygen atom to which it is attached defines an O-linked substituent other than —OH;
the circled moiety represents a 5-membered nitrogen-containing heteroarylene, wherein the indicated required substituents to that heteroarylene are in a 1,3-relationship with each other with optional substitution at the remaining positions;
R3 is hydrogen or optionally substituted C1-C12 alkyl;
R4, R5 and R6 are optionally substituted C1-C12 alkyl, independently selected;
one R7 is hydrogen or optionally substituted C1-C12 alkyl and the other R7 is optionally substituted (C6-C20 aryl)-C1-C12 alkyl- or (C5-C20 heteroaryl)-C1-C12 alkyl-;
wherein the wavy line indicates the point of covalent attachment of D+ to the remainder of the compound structure.